Linvoseltamab Wins EU Approval for Hard-to-Treat Multiple Myeloma
Regeneron's bispecific antibody linvoseltamab earns EU approval for relapsed/refractory multiple myeloma after at least three prior therapies.
Summary
Linvoseltamab (Lynozyfic) is a newly EU-approved bispecific antibody for multiple myeloma patients who have exhausted standard treatments. Developed by Regeneron, it works by simultaneously binding to BCMA on malignant plasma cells and CD3 on T cells, essentially directing the immune system to destroy cancer cells. The EU approved it in April 2025 for adults with relapsed or refractory multiple myeloma who have previously received at least three therapies — including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody — and whose disease has progressed on their most recent treatment. This approval marks a meaningful advance for a patient population with very limited remaining options, and it adds to the growing class of T cell-engaging bispecific antibodies reshaping blood cancer treatment.
Detailed Summary
Multiple myeloma is a blood cancer with a chronic, relapsing course. For patients who have already failed three or more lines of therapy — including drugs from the three main classes used in myeloma — prognosis is poor and treatment options are scarce. The approval of linvoseltamab represents a meaningful step forward for this underserved population.
Linvoseltamab (brand name Lynozyfic) is a fully human bispecific antibody developed by Regeneron Pharmaceuticals. It targets two distinct proteins simultaneously: B cell maturation antigen (BCMA), which is highly expressed on malignant myeloma plasma cells, and CD3, a surface protein on T cells. By bridging these two cell types, linvoseltamab redirects the patient's own immune T cells to recognize and kill cancer cells — a mechanism known as T cell redirection.
On April 28, 2025, linvoseltamab received its first regulatory approval from the European Union. It is indicated as monotherapy for adult patients with relapsed or refractory multiple myeloma who have received at least three prior therapies including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have shown disease progression on their last treatment. This positions it alongside a small but growing class of BCMA-targeting agents.
The approval underscores the rapid evolution of bispecific antibodies in oncology. Unlike CAR-T therapies, which require complex manufacturing and a single infusion, bispecific antibodies are off-the-shelf drugs administered via standard infusion, making them more accessible to patients globally.
Caveats apply: this summary is derived from a regulatory milestone article rather than the underlying clinical trial data. Full efficacy and safety profiles, including response rates and cytokine release syndrome incidence, require review of primary trial publications for complete clinical context.
Key Findings
- Linvoseltamab received EU approval April 28, 2025 for relapsed/refractory multiple myeloma.
- It targets BCMA on myeloma cells and CD3 on T cells to redirect immune killing.
- Approved for patients who failed ≥3 prior therapies including all three major drug classes.
- Developed by Regeneron as an off-the-shelf alternative to CAR-T cell therapies.
- First approval is as monotherapy; additional indications are under investigation.
Methodology
This article is a regulatory milestone review published in Drugs, summarizing the development history and approval pathway of linvoseltamab. It does not present original clinical trial data but synthesizes key milestones leading to EU authorization. The underlying approval was based on clinical trial evidence reviewed by the European Medicines Agency.
Study Limitations
This summary is based on the abstract only, as the full article is not open access; detailed efficacy data, response rates, and safety profiles are not available from this source alone. The article is a regulatory review rather than a primary clinical trial report, so quantitative outcomes require consultation of the original trial publications. Generalizability of EU approval criteria to other regulatory jurisdictions such as the FDA has not yet been established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.